Zhong Xinwen, Chen Xiaolong, Guan Xiaojiao, Zhang Heng, Ma Yinan, Zhang Shuguang, Wang Enhua, Zhang Lin, Han Yuchen
Department of Thoracic Surgery, The First Affiliated Hospital, China Medical University, Shenyang, China.
Histopathology. 2015 Jan;66(2):192-200. doi: 10.1111/his.12456. Epub 2014 Nov 13.
Histone methyltransferase G9a has been primarily understood as a co-repressor of gene expression, but it has been shown that G9a also positively regulates nuclear receptor-mediated transcription. MCM7, a critical component of the DNA replication licensing complex, is amplified and overexpressed in a variety of human malignancies. The objectives of the present study were to study the relationship between the expression of G9a and MCM7 and the pathological grade, clinical stage and prognosis of oesophageal squamous cell carcinoma (OSCC).
We collected 139 formalin-fixed and paraffin-embedded tissues from patients with OSCC and surveyed them by tissue microarray-based immunohistochemical staining. Associations between the expression of MCM7 and G9a and clinicopathological parameters and prognosis of OSCC were examined. From tissue microarray immunohistochemistry staining results, we found that nuclear staining intensity for MCM7 and G9a was associated with histological grade (both P < 0.001), tumour depth (P = 0.050, 0.034), lymph node metastasis (P = 0.001, 0.009) and tumour stage (P < 0.001, =0.003). G9a expression was correlated with that of MCM7. G9a overexpression independently predicted poor cancer-specific survival in OSCC (hazard ratio 0.05, 95% confidence interval 0.006-0.417, P = 0.006) and MCM7 (hazard ratio 0.05, 95% confidence interval 0.013-0.441, P = 0.004). OSCC patients whose tumours showed double-positive expression of G9a and MCM7 (G9a(+) MCM7(+) ) had much shorter survival than those from either the G9a or MCM7 low expression groups (G9a(-) MCM7(-) , G9a(+) MCM7(-) , G9a(-) MCM7(+) ).
MCM7 and G9a may serve as effective prognostic factors and could also be used as biomarkers for predicting various clinical outcomes of OSCCs in the Chinese population.
组蛋白甲基转移酶G9a主要被认为是基因表达的共抑制因子,但研究表明G9a也正向调控核受体介导的转录。微小染色体维持蛋白7(MCM7)是DNA复制许可复合物的关键组成部分,在多种人类恶性肿瘤中呈扩增及过表达状态。本研究旨在探讨G9a与MCM7的表达与食管鳞状细胞癌(OSCC)病理分级、临床分期及预后的关系。
收集139例OSCC患者的福尔马林固定石蜡包埋组织,采用组织芯片免疫组化染色进行检测。分析MCM7与G9a的表达与OSCC临床病理参数及预后的相关性。从组织芯片免疫组化染色结果发现,MCM7和G9a的核染色强度与组织学分级(均P<0.001)、肿瘤深度(P=0.050,0.034)、淋巴结转移(P=0.001,0.009)及肿瘤分期(P<0.001,=0.003)相关。G9a表达与MCM7相关。G9a过表达独立预测OSCC患者较差的癌症特异性生存(风险比0.05,95%置信区间0.006-0.417,P=0.006)以及MCM7(风险比0.05,95%置信区间0.013-0.441,P=0.所004)。肿瘤呈现G9a和MCM7双阳性表达(G9a(+)MCM7(+))的OSCC患者的生存时间明显短于G9a或MCM7低表达组(G9a(-)MCM7(-)、G9a(+)MCM7(-)、G9a(-)MCM7(+))的患者。
MCM7和G9a可能是有效的预后因素,也可作为预测中国人群OSCC各种临床结局的生物标志物。